Who is Ironwood?

Our vision is clear: bring new, differentiated therapies to the millions of patients who live with GI diseases.

Building on a strong, decades-long foundation, the next leg of our journey continues with three innovative assets. Our in-market product, LINZESS® (linaclotide), discovered in-house, is the branded prescription market leader in its class. We are also pioneering the science behind our two development programs, IW-3718 and MD-7246, which aim to address two highly symptomatic conditions with significant unmet needs.